{
    "symbol": "RETA",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 11:57:03",
    "content": " In addition to the updated delayed start and propensity match analyses, we provided additional mechanistic evidence to the division that included an integrated and detailed presentation of the disease pathophysiology of FA linking for tax and deficiency with Nrf2 suppression and impaired mitochondrial function, mechanism of action data showing that Omav restores Nrf2 activity and mitochondrial energy production in preclinical FA models and FA patient fibroblast and clinical biomarker data demonstrating that induction of Nrf2 targets in Omav treated patients in the MOXIe Part 2 trial was associated with improvements in mFARS scores."
}